3 Vaccine, Formulation and Pharmacy Chain Stocks With a Strong Future Roadmap: GlaxoSmithKline Pharmaceuticals, Lincoln Pharmaceuticals and Medplus Health Services
- October 13, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
GSK Pharma Rs 2,531.50, P/E 40.20. Lincoln Pharma Rs 543.50, P/E 11.64. Medplus Rs 627.60, P/E 36.06. Closing prices of 12 Oct 2026.
Quick Answer
Vaccine, formulation and pharmacy chain stocks with the clearest long-term roadmaps today include GSK Pharma in branded medicines and vaccines, Lincoln Pharma in formulations for India and export markets and Medplus in a pharmacy retail chain across several states. FY26 revenue growth was 1.8% at GSK Pharma, 9.1% at Lincoln Pharma and 12.6% at Medplus. P/E stands at 40.20 for GSK Pharma (industry 37.59), 11.64 for Lincoln Pharma (industry 37.59) and 36.06 for Medplus (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Vaccine, formulation and pharmacy chain stocks give investors exposure to medicines, vaccines and pharmacy stores that patients use regularly. Prescription growth, store additions and margins decide how much of that demand turns into profit.
This list covers three vaccine, formulation and pharmacy chain stocks: GlaxoSmithKline Pharmaceuticals for branded medicines and vaccines, Lincoln Pharmaceuticals for formulations for India and export markets and Medplus Health Services for a pharmacy retail chain across several states. Every figure comes from the latest reported financials and the 12 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Vaccine, Formulation and Pharmacy Chain Stocks?
Vaccine, formulation and pharmacy chain stocks are shares of companies that make medicines and vaccines or sell them through pharmacy stores. Results depend on prescription growth, store additions and margins, so growth and margins separate the stronger names.
Vaccine, Formulation and Pharmacy Chain Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three vaccine, formulation and pharmacy chain stocks as of the 12 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals | 2,531.50 | 42,939 | 40.20 | 37.59 | 45.69% | 0.01 |
| Lincoln Pharmaceuticals | 543.50 | 1,123 | 11.64 | 37.59 | 11.60% | 0.01 |
| Medplus Health Services | 627.60 | 7,589 | 36.06 | 66.59 | 11.12% | 0.72 |
Among pharma and healthcare retail stocks, GSK Pharma trades at a premium to the industry P/E, while Lincoln Pharma and Medplus trade at a discount.
Why Do Vaccine, Formulation and Pharmacy Chain Stocks Have a Strong Roadmap in India?
Vaccine, formulation and pharmacy chain stocks have a strong roadmap in India because health spending, vaccination reach and organised pharmacy growth keep lifting demand for medicine makers and pharmacy chains. Three drivers stand out.
- Health spending: More families buy medicines and treatment regularly.
- Vaccine reach: Immunisation programmes widen the user base.
- Organised retail: Pharmacy chains gain share from small stores.
GlaxoSmithKline Pharmaceuticals: Branded Medicines and Vaccines Anchor the Roadmap
GSK Pharma’s roadmap rests on branded medicines and vaccines sold through a large doctor network, with established brands supporting steady sales.
Revenue grew from Rs 3,353.80 crore in FY22 to Rs 3,967.03 crore in FY26, an 18.3% rise, and FY26 revenue was 1.8% higher than FY25. FY26 net profit rose 11.7% to Rs 1,035.98 crore. Over four years, net profit rose from Rs 380.77 crore in FY22 to Rs 1,035.98 crore. In Q1 FY27, revenue grew 15.7% to Rs 982.20 crore, and net profit rose 15.7% to Rs 237.18 crore. Operating margin was 38.60% in FY26.
Debt to equity is 0.01 and return on equity is 45.69%. FY26 operating cash flow was Rs 903.30 crore against capital expenditure of Rs 55.28 crore. GSK Pharma paid a dividend of Rs 57 per share for FY26, a yield of 2.25%. At a P/E of 40.20 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: The P/E of 40.20 is a modest premium to the industry P/E of 37.59, so the next quarters’ growth is the figure to follow.
Lincoln Pharmaceuticals: Formulations for India and Export Markets Build the Next Leg
Lincoln Pharma’s roadmap rests on formulations sold in India and emerging export markets, with a broad product list supporting revenue.
Revenue grew from Rs 482.12 crore in FY22 to Rs 704.48 crore in FY26, a 46.1% rise, and FY26 revenue was 9.1% higher than FY25. FY26 net profit rose 6.7% to Rs 87.89 crore. Over four years, net profit rose from Rs 69.36 crore in FY22 to Rs 87.89 crore. In Q1 FY27, revenue grew 19.0% to Rs 201.54 crore, and net profit rose 30.9% to Rs 36.23 crore.
Debt to equity is 0.01 and return on equity is 11.60%. The dividend yield is 0.32%. At a P/E of 11.64 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: The P/E of 11.64 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Medplus Health Services: Pharmacy Retail Stores Anchor the Roadmap
Medplus’ roadmap rests on a pharmacy retail chain with stores across several states, with store expansion supporting revenue.
Revenue grew from Rs 3,810.64 crore in FY22 to Rs 6,963.79 crore in FY26, an 82.7% rise, and FY26 revenue was 12.6% higher than FY25. FY26 net profit rose 46.2% to Rs 219.61 crore. Over four years, net profit rose from Rs 94.72 crore in FY22 to Rs 219.61 crore. In Q1 FY27, revenue grew 21.9% to Rs 1,899.43 crore. Operating margin was 9.85% in FY26.
Debt to equity is 0.72 and return on equity is 11.12%. FY26 operating cash flow was Rs 495.58 crore against capital expenditure of Rs 123.03 crore. At a P/E of 36.06 against an industry P/E of 66.59, the stock trades below its industry multiple.
What to watch: Net profit margin is only 3.2%, so small cost changes move earnings.
Best Vaccine, Formulation and Pharmacy Chain Stocks in India: GSK Pharma vs Lincoln Pharma vs Medplus on Key Financials
Among the best vaccine, formulation and pharmacy chain stocks in India, GSK Pharma leads on return on equity and the lowest debt to equity; Lincoln Pharma leads on the lowest P/E; Medplus leads on FY26 revenue growth and Q1 FY27 revenue growth. The table puts the numbers side by side.
| Metric | GSK Pharma | Lincoln Pharma | Medplus |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 3,967.03 | 704.48 | 6,963.79 |
| FY26 revenue growth | 1.8% | 9.1% | 12.6% |
| FY26 net profit (Rs Cr) | 1,035.98 | 87.89 | 219.61 |
| FY26 net profit growth | 11.7% | 6.7% | 46.2% |
| Q1 FY27 revenue growth (YoY) | 15.7% | 19.0% | 21.9% |
| Return on equity | 45.69% | 11.60% | 11.12% |
| P/E ratio | 40.20 | 11.64 | 36.06 |
| Debt to equity | 0.01 | 0.01 | 0.72 |
| Dividend yield | 2.25% | 0.32% | 0.00% |
Pharma earnings follow prescription growth, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Vaccine, Formulation and Pharmacy Chain Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen vaccine, formulation and pharmacy chain stocks and shortlist vaccine, formulation and pharmacy chain stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and return on equity together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these vaccine, formulation and pharmacy chain stocks
Risks to Consider Before Investing in Vaccine, Formulation and Pharmacy Chain Stocks
- Pricing rules: Price controls can affect margins.
- Competition: Online and offline rivals can pressure sales.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track GSK Pharma, Lincoln Pharma and Medplus live.
Annual reports and quarterly result presentations are the most reliable places to verify the numbers quoted here, because they show segment details, management commentary and the notes behind each figure.
Comparing a quarter with the same quarter of the previous year gives a cleaner reading than comparing it with the preceding quarter, since seasonal patterns affect many businesses in India.
The shareholding pattern published every quarter shows whether promoters, mutual funds and foreign investors are raising or trimming their holdings, which adds useful context to the financial numbers.
Spreading money across several sectors and company sizes helps keep a portfolio steady, because each business responds differently to interest rates, commodity prices and consumer demand.
Final Take: Which Stock Has the Strongest Roadmap?
These three pharma and healthcare retail stocks cover branded medicines and vaccines, formulations and a pharmacy retail chain. GSK Pharma leads on return on equity and the lowest debt to equity; Lincoln Pharma leads on the lowest P/E; Medplus leads on FY26 revenue growth and Q1 FY27 revenue growth.
Across vaccine, formulation and pharmacy chain stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the vaccine, formulation and pharmacy chain stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Vaccine, Formulation and Pharmacy Chain Stocks
Which are the best vaccine, formulation and pharmacy chain stocks in India with a strong roadmap?
Ans. GlaxoSmithKline Pharmaceuticals, Lincoln Pharmaceuticals and Medplus Health Services stand out for their roadmaps in branded medicines and vaccines, formulations and a pharmacy retail chain. FY26 revenue growth was 1.8% at GSK Pharma, 9.1% at Lincoln Pharma and 12.6% at Medplus, and return on equity ranges from 11.12% to 45.69%.
Is GlaxoSmithKline Pharmaceuticals a good stock to buy now?
Ans. GlaxoSmithKline Pharmaceuticals has a debt to equity ratio of 0.01, a return on equity of 45.69% and a P/E of 40.20 against an industry P/E of 37.59. Valuation, growth and pricing rules move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of GSK Pharma, Lincoln Pharma and Medplus?
Ans. The P/E ratio is 40.20 for GSK Pharma (industry 37.59), 11.64 for Lincoln Pharma (industry 37.59) and 36.06 for Medplus (industry 66.59). Only GSK Pharma trades at or above the industry multiple.
Which of these vaccine, formulation and pharmacy chain stocks has the highest return on equity?
Ans. GlaxoSmithKline Pharmaceuticals has the highest return on equity at 45.69%, followed by Lincoln Pharmaceuticals at 11.60% and Medplus Health Services at 11.12%.
What are the risks of investing in vaccine, formulation and pharmacy chain stocks?
Ans. The main risks are pricing rules, competition and quarterly trends. Price controls can affect margins.
How did GSK Pharma, Lincoln Pharma and Medplus perform in Q1 FY27?
Ans. GlaxoSmithKline Pharmaceuticals reported revenue of Rs 982.20 crore, up 15.7% year on year, and net profit rose 15.7% to Rs 237.18 crore. Lincoln Pharmaceuticals reported revenue of Rs 201.54 crore, up 19.0% year on year, and net profit rose 30.9% to Rs 36.23 crore. Medplus Health Services reported revenue of Rs 1,899.43 crore, up 21.9% year on year.
Do vaccine, formulation and pharmacy chain stocks pay dividends?
Ans. GSK Pharma and Lincoln Pharma pay dividends. The dividend yield is 2.25% for GSK Pharma and 0.32% for Lincoln Pharma, based on dividends declared for FY26.
How can I invest in vaccine, formulation and pharmacy chain stocks in India?
Ans. You can buy vaccine, formulation and pharmacy chain stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
